Goods & Services

Safes; locks of metal; safety boxes; strongboxes; electronic safes. Software and application software; software and application software, all for use in enabling the operation of and interaction and interface between mobile devices and electronic safes; authentication software; digital locks; biometric locks; electric locks; electronic locking mechanisms for safes; electronic locks and access control apparatus; electronic locking systems and apparatus for safes; computer programs for controlling electric locks; software and application software for mobile devices, namely, software for use in mental health and well-being support. Software as a service [SaaS]; software as a service [SaaS] featuring software for use in enabling the operation of and interaction and interface between mobile devices and electronic safes; user authentication services for online software applications; user authentication services using sign-on technology for online software applications; authentication services of data transmitted via telecommunications; application service provider featuring a software application for use in connection with electric and electronic safes; design and development of software. Rental of safes.

Abstract

The disclosure concerns use of a compound for treating a lysosomal storage disorder, increasing lysosomal clearance, reducing a neurological pathology or reducing seizures. The disclosure further concerns a method for treating a lysosomal storage disorder, increasing lysosomal clearance, reducing a neurological pathology or reducing seizures, which comprises administering a compound to a subject. The disclosure also concerns use of a compound in the manufacture of a medicament for use in treating one or more symptoms of a lysosomal storage disorder, increasing lysosomal clearance, reducing a neurological pathology or reducing seizures. In any case, the compound is steroid, a GABA receptor ligand, a Sigma-1 receptor ligand, a cannabinoid receptor ligand, a TRP channel ligand and/or a microtubule modulator.

IPC Classes  ?

• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention provides means and methods for the non-invasive diagnosis of intestinal infection in birds.

IPC Classes  ?

• C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa

Abstract

The present disclosure relates to a method of treating or preventing a disease in an individual, the method comprising reducing pyroptosis by administering to the individual a composition comprising an agent whose administration reduces TSPO signalling in the individual. The method of the disclosure can thus be used to treat or prevent diseases associated with pyroptosis such as inflammatory disease, cancer, neurodegenerative disease, cardiovascular disease, kidney disease and sepsis. The disclosure also relates to use of TSPO expression as a biomarker for pyroptosis, a method of assessing the degree of pyroptosis in an individual based on TSPO expression, an in vitro model of pyroptosis, a method of producing the in vitro model and associated vector, and a method for determining the ability of an agent to inhibit pyroptosis.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

There are provided compounds of formula (I): [hyaluronan production inhibitor]-[labile linker]-X (I), which compounds are useful in the treatment of diseases associated with hyaluronan overproduction.

IPC Classes  ?

• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group

Abstract

The disclosure concerns a method for detecting the presence or absence of mycobacteria in a sample and a method for diagnosing the presence or absence of a mycobacterial infection in a subject. The disclosure also concerns a lysis agent comprising bacteriophage capable of lysing viable mycobacteria and use of the lysis agent in the methods of the disclosure.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Goods & Services

(1) Safes; locks of metal; safety boxes; strongboxes; electronic safes. (2) Software and application software; software and application software, all for use in enabling the operation of and interaction and interface between mobile devices and electronic safes; authentication software; digital locks; biometric locks; electric locks; electronic locking mechanisms for safes; electronic locks and access control apparatus; electronic locking systems and apparatus for safes; computer programs for controlling electric locks; software and application software for mobile devices, namely, software for use in mental health and well-being support. (1) Software as a service [SaaS]; software as a service [SaaS] featuring software for use in enabling the operation of and interaction and interface between mobile devices and electronic safes; user authentication services for online software applications; user authentication services using sign-on technology for online software applications; authentication services of data transmitted via telecommunications; application service provider featuring a software application for use in connection with electric and electronic safes; design and development of software. (2) Rental of safes.

Goods & Services

Safes; locks of metal; safety boxes; strongboxes; electronic safes. Software and application software; software and application software, all for use in enabling the operation of and interaction and interface between mobile devices and electronic safes; authentication software; digital locks; biometric locks; electric locks; electronic locking mechanisms for safes; electronic locks and access control apparatus; electronic locking systems and apparatus for safes; computer programs for controlling electric locks; software and application software for mobile devices, namely, software for use in mental health and well-being support. Software as a service [SaaS]; software as a service [SaaS] featuring software for use in enabling the operation of and interaction and interface between mobile devices and electronic safes; user authentication services for online software applications; user authentication services using sign-on technology for online software applications; authentication services of data transmitted via telecommunications; application service provider featuring a software application for use in connection with electric and electronic safes; design and development of software. Rental of safes.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The disclosure relates to a method of screening a dog for a predisposition to diabetes mellitus, and a method of determining the potential of a dog to produce progeny that are genetically predisposed to diabetes mellitus. The disclosure also relates to a method of selecting a treatment for diabetes mellitus in a dog, a method of preventing, delaying or treating diabetes mellitus in a dog using an oral hypoglycaemic drug, and a composition comprising an oral hypoglycaemic drug for use in a method of preventing, delaying or treating diabetes mellitus in a dog. The disclosure further concerns a method of preventing or delaying diabetes mellitus in a dog using an anti-hyperglycaemic diet or by means of neutering, and an anti-hyperglycaemic diet for use in a method of preventing or delaying diabetes mellitus in a dog.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The disclosure concerns a method of treating a disorder characterised by chondrocyte hypertrophy e.g. osteoarthritis, and a composition for use in such a method. The disclosure also concerns a method of producing a miniaturised model of endochondral ossification, and a miniaturised model of endochondral ossification producible by such method. The disclosure further provides a method of screening for compositions for use in treating a disorder characterised by chondrocyte hypertrophy, and a composition identified by such method.

IPC Classes  ?

• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions

IPC Classes  ?

• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to method of diagnosing stage B2 degenerative mitral valve disease (DMVD) in a dog, a method of determining the probability of a dog having stage B2 DMVD, a method of training a model to predict stage B2 DMVD in a dog, and a related computer program and system.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention provides means and methods for the non-invasive diagnosis of intestinal infection in birds.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

The present invention provides means and methods for the non-invasive diagnosis of intestinal infection in birds.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

in vitroin vitroin vitro model and associated vector, and a method for determining the ability of an agent to inhibit pyroptosis.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12Q 3/00 - Condition-responsive control processes
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C40B 30/00 - Methods of screening libraries

Abstract

There are provided compounds of formula (I): [hyaluronan production inhibitor][labile linker]X (I), which compounds are useful in the treatment of diseases associated with hyaluronan overproduction.

IPC Classes  ?

• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07C 327/30 - Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
• C07D 277/22 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

There are provided compounds of formula (I): [hyaluronan production inhibitor]—[labile linker]—X (I), which compounds are useful in the treatment of diseases associated with hyaluronan overproduction.

IPC Classes  ?

• C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
• C07C 327/30 - Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
• C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
• C07D 277/22 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides an aircraft (10) for flying in a forward direction (F). The aircraft (10) comprises an aircraft body (20), and a wing comprising a first wing portion (30A) and a second wing portion (30B). The first wing portion (30A) and the second wing portion (30B) extend away from the aircraft body (20). The first wing portion (30A) and the second wing portion (30B) are configured to generate a first lift value during level flight of the aircraft (10) in the forward direction (F) when the first wing portion (30A) and the second wing portion (30B) are in an equilibrium position. Each of the first wing portion (30A) and the second wing portion (30B) is flexibly mounted relative to the aircraft body (20) such that when a lift force generated by the first wing portion (30A) changes from the first lift value to a second lift value, the first wing portion (30A) is deflected substantially vertically away from an equilibrium position. The aircraft (10) is configured to provide a further force to the first wing portion (30A) to substantially prevent further deflection of the first wing portion (30A) away from the equilibrium position.

IPC Classes  ?

• B64C 3/42 - Adjusting about chordwise axes
• B64C 39/02 - Aircraft not otherwise provided for characterised by special use

Abstract

The invention relates to method of diagnosing stage B2 degenerative mitral valve disease (DMVD) in a dog, a method of determining the probability of a dog having stage B2 DMVD, a method of training a model to predict stage B2 DMVD in a dog, and a related computer program and system.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Abstract

The invention relates to method of diagnosing stage B2 degenerative mitral valve disease (DMVD) in a dog, a method of determining the probability of a dog having stage B2 DMVD, a method of training a model to predict stage B2 DMVD in a dog, and a related computer program and system.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A mobile device (10) capable of autonomous travel comprises drive means (12, 13) to provide movement of the device over a surface and an obstacle detecting and movement influencing system (15, 16, 17) to detect an obstacle (20) in the path of the device and in response to detection of an obstacle to control the drive means to influence movement of the device. The obstacle detecting and movement influencing system comprises a pneumatic element (15) which is positioned on a body (11) of the device to face in the forward direction of movement of the device and which is resiliently compressible on contact with an obstacle (20). The device (10) includes a control unit (18) responsive to sensing by a sensor (17) of the contact to then control the drive means (12, 13) so as to cause travel of the device in the direction of forward movement to be arrested and subsequently resumed in that direction after a delay, during which the device may remain stationary, execute reverse travel and/or execute a bypass routine.

IPC Classes  ?

• G05D 1/02 - Control of position or course in two dimensions

Abstract

The present disclosure provides an aircraft (10) for flying in a forward direction (F). The aircraft (10) comprises an aircraft body (20), and a wing comprising a first wing portion (30A) and a second wing portion (30B). The first wing portion (30A) and the second wing portion (30B) extend away from the aircraft body (20). The first wing portion (30A) and the second wing portion (30B) are configured to generate a first lift value during level flight of the aircraft (10) in the forward direction (F) when the first wing portion (30A) and the second wing portion (30B) are in an equilibrium position. Each of the first wing portion (30A) and the second wing portion (30B) is flexibly mounted relative to the aircraft body (20) such that when a lift force generated by the first wing portion (30A) changes from the first lift value to a second lift value, the first wing portion (30A) is deflected substantially vertically away from an equilibrium position. The aircraft (10) is configured to provide a further force to the first wing portion (30A) to substantially prevent further deflection of the first wing portion (30A) away from the equilibrium position.

IPC Classes  ?

• B64C 3/42 - Adjusting about chordwise axes
• B64C 39/02 - Aircraft not otherwise provided for characterised by special use

Abstract

A vehicle includes a propulsion unit configured to move the vehicle and to change a characteristic of the environment of the vehicle. The vehicle also includes a proximity sensor configured to detect the characteristic of the environment of the vehicle. The characteristic of the environment is changed by operation of the propulsion unit. The vehicle further includes obstacle detection circuitry configured to determine a presence of an obstacle in the vicinity of the vehicle based on a comparison between the detected characteristic of the environment and a reference value.

IPC Classes  ?

• G05D 1/00 - Control of position, course, altitude or attitude of land, water, air or space vehicles, e.g. using automatic pilots
• G06V 20/58 - Recognition of moving objects or obstacles, e.g. vehicles or pedestriansRecognition of traffic objects, e.g. traffic signs, traffic lights or roads
• B64C 13/16 - Initiating means actuated automatically, e.g. responsive to gust detectors
• B64C 39/02 - Aircraft not otherwise provided for characterised by special use
• G05D 1/02 - Control of position or course in two dimensions
• G08G 1/16 - Anti-collision systems

Abstract

There is provided a vehicle (18) comprising a propulsion unit (34) configured to move the vehicle (18) and to change a characteristic of the environment of the vehicle (18). The vehicle (18) further comprises a proximity sensor (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31) configured to detect the characteristic of the environment of the vehicle. The characteristic of the environment is changed by operation of the propulsion unit (34). The vehicle (18) further comprises obstacle detection circuitry (32) configured to determine a presence of an obstacle in the vicinity of the vehicle based on a comparison between the detected characteristic of the environment and a reference value.

IPC Classes  ?

• B64U 10/14 - Flying platforms with four distinct rotor axes, e.g. quadcopters
• B64U 10/80 - UAVs characterised by their small size, e.g. micro air vehicles [MAV]
• G01V 11/00 - Prospecting or detecting by methods combining techniques covered by two or more of main groups
• G08G 5/80 - Anti-collision systems
• G08G 9/02 - Anti-collision systems

Abstract

There is provided a vehicle (18) comprising a propulsion unit (34) configured to move the vehicle (18) and to change a characteristic of the environment of the vehicle (18). The vehicle (18) further comprises a proximity sensor (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31) configured to detect the characteristic of the environment of the vehicle. The characteristic of the environment is changed by operation of the propulsion unit (34). The vehicle (18) further comprises obstacle detection circuitry (32) configured to determine a presence of an obstacle in the vicinity of the vehicle based on a comparison between the detected characteristic of the environment and a reference value.

IPC Classes  ?

• B64C 39/02 - Aircraft not otherwise provided for characterised by special use
• G01S 15/93 - Sonar systems specially adapted for specific applications for anti-collision purposes
• G08G 5/00 - Traffic control systems for aircraft
• G08G 5/04 - Anti-collision systems

Goods & Services

Databases (electronic); computer databases; databases for the collation of information relating to companion animal epidemiology; databases for the collation of information relating to animal livestock; databases for the collation of information relating to medical, pharmaceutical and veterinary practices; databases for the collation and compilation of clinical notes, research and data. Management and operation of a computer database in the medical, pharmaceutical and veterinary fields; management and operation of a computer database relating to companion animal epidemiology; management and operation of a computer database relating to animal livestock; data input and compilation; compilation, collation and management of information from medical and veterinary practices; compilation, collation and management of clinical notes and data; compilation, collation and management of primary data and secondary data; compilation, collation and management of medical and veterinary information and data for use in the medical, pharmaceutical and veterinary fields; compilation, analysis and retrieval of information and data; compilation and systemisation of information into computer databases; information, advisory and consultancy services relating to all of the aforesaid. Education and training services in the medical, pharmaceutical and veterinary fields; education and training services in the field of companion animal epidemiology; education and training services in the field of animal livestock; educational and training information provided from a computer database; veterinary, medical and pharmaceutical educational and training information provided from a computer database; companion animal epidemiology educational and training information provided from a computer database; animal livestock educational and training information provided from a computer database; educational and training services relating to the veterinary, pharmaceutical and medical professions; educational and training services relating to clinical data and research; educational and training services relating to the use of a computer database and the information contained therein; information, advisory and consultancy services relating to all of the aforesaid services. Scientific and technological services in the medical, pharmaceutical and veterinary fields; research and consulting services in the medical, pharmaceutical and veterinary fields; design and development of a computer database for the compilation, collation, analysis and management of information in the medical, pharmaceutical and veterinary fields; design and development of a computer database for assisting with research in the medical, pharmaceutical and veterinary fields; design and development of a computer database for clinical research; research and analytical services in the medical, pharmaceutical and veterinary fields; scientific and research services in the field of companion animal epidemiology; scientific and research services in the field of animal livestock; design and development of a computer database in the field of companion animal epidemiology; design and development of a computer database in the field of animal livestock; design and development of a computer database for collating clinical information; design and development of a computer database for providing the medical, pharmaceutical and veterinary industries with information and data collated from clinical notes and research from medical and veterinary practices; information, advisory and consultancy services relating to all of the aforesaid. Provision of medical, veterinary and pharmaceutical information to others; information services relating to the medical, veterinary and pharmaceutical industries; provision of information relating to clinical data and research; provision of information to the veterinary, medical and pharmaceutical industries relating to clinical data and research; provision of information relating to companion animal epidemiology; provision of information relating to animal livestock; provision of information to the veterinary, medical and pharmaceutical industries relating to companion animal epidemiology; provision of information to the veterinary, medical and pharmaceutical industries relating to animal livestock; provision of research data in the medical, pharmaceutical and veterinary fields; provision of research data to the veterinary, medical and pharmaceutical industries; information, advisory and consultancy services relating to all of the aforesaid services.

Abstract

A preparation of an inactivated or freeze-dried yeast cell (or cell-surface-containing portion thereof) expressing a porcine viral epitope, wherein the epitope is expressed on the surface of the yeast cell. The yeast is typically is non-viable. The yeast is typically from the genus Saccharomyces, and is preferably Saccharomyces cerevisiae, but may be from the genus Pichia, for example Pichia pastoris, or may be from the genus Kluyveromyces, for example K. lactis. The viral epitope may be from a Coronavirus, optionally from PEDV, TGEV, porcine hemagglutinating encephalomyelitis virus or PRCV; a porcine Rotavirus; or a virus of the Circoviridae family, optionally from PCV2.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

Low molecular weight hyaluronic acid (LMWHA) or very low molecular weight hyaluronic acid (VLMWHA) or PH20 for use in the culture of an embryo, zygote, blastocyst and/or an oocyte. A composition comprising low molecular weight hyaluronic acid (LMWHA) and/or very low molecular weight hyaluronic acid (VLMWHA) and/or PH20 may be used in the culture of an embryo, zygote, blastocyst and/or an oocyte. The LMWHA may be between 15kDa and 40kDa in size. The VLMWHA may be <10kDa, optionally the VLMWHA is a tetrasaccharide or a hexasaccharide, optionally the VLMWHA is 4-8 monosaccharides or less in size. A method for selecting an embryo or blastocyst generated through assisted fertilisation, optionally in vitro fertilisation or ICSI, as suitable for implantation, wherein the method comprises determination of the level of hyal-2 in the culture medium used to culture the embryo or blastocyst.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

The present invention relates to compositions and methods for the treatment of obligate or facultative intracellular microorganisms, such as bacteria, fungi or parasites such as protozoan parasites. The present invention also relates to compositions and methods for enhancing immune cell activation, for example macrophage, dendritic cell, monocytes and lymphocyte activation, which is considered to be useful in treating infection, cancer and asthma, for example.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/002 - Protozoa antigens
• A61K 39/008 - Leishmania antigens
• A61K 39/085 - Staphylococcus

Abstract

A method for assessing whether a test substance or treatment is potentially neuroprotective or anti-oxidant, the method comprising the steps of exposing a cell to the test substance or treatment assessing the TSPO level in the cell, wherein a substance or treatment is considered to be potentially anti-oxidant and/or neuroprotective if the TSPO level is decreased. The method may comprise the step of assessing the level of mitophagy in the cell, wherein a substance or treatment is considered to be anti-oxidant or neuroprotective if the level or induction of mitophagy is increased and the TSPO level is decreased.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The disclosure relates to a sole (10) for an item of footwear (12), comprising: a toe portion (14); a heel portion (16); and a kinetic energy absorbing member (18) situated between heel and toe portions and having an extended position in which the kinetic energy absorbing member protrudes further from the sole than the heel portion and a retracted position in which the kinetic energy absorbing member protrudes no further from the sole than the heel portion.

IPC Classes  ?

• A43B 13/18 - Resilient soles
• A43B 5/06 - Running shoesTrack shoes
• A43B 7/14 - Footwear with health or hygienic arrangements with foot-supporting parts

Abstract

A sole for an item of footwear comprising: • a front portion; • a heel portion; and • a energy absorbing member positioned within the front portion, and having a first position in which the energy absorbing member protrudes from the sole, and a second position in which the energy absorbing member is substantially level with a surface of the sole.

IPC Classes  ?

• A43B 13/18 - Resilient soles
• A43B 5/06 - Running shoesTrack shoes
• A43B 7/14 - Footwear with health or hygienic arrangements with foot-supporting parts

Abstract

A compound comprising a C-type lectin Carbohydrate Recognition Domain (CRD) and an immunoglobulin Fc domain for use in treating or preventing a pathogen infection in a non-human, non-murine subject. Preferably the non-human, non-murine subject is not considered to be an immunocompromised or immunosuppressed subject. The non- human, non-murine subject may be a ruminant; a livestock; companion or racing animal. The CRD, immunoglobulin Fc domain and the non-human, non-murine subject may be bovine. The pathogen infection typically comprises infection by a bacterium, optionally Staphylococcus aureus or Streptococcus Uberis or Streptococcus Agalactiae/dysgalactiae. The subject (for example bovine subject) may have mastitis, subclinical mastitis, actue mastitis, chronic mastitis, high somatic cell count (high SSC), metritis or endometritis. The non-human, non-murine subject may typically be further administered an antibiotic or antifungal agent. The CRD may be from bovine Mannose binding Lectin (MBL) and the immunoglobulin Fc domain may be an lgG1 Fc domain.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

A plasmid for transforming Mycoplasma hyopneumoniae comprising an OriC region comprising both AT-rich regions from a predicted OriC region of M. hyopneumoniae 232, or comprising a variant thereof that retains the ability to act as an OriC region in M. hyopneumoniae and has at least 90% sequence identity with a sequence comprising both AT-rich regions from a predicted OriC region of M. hyopneumoniae 232. A M. hyopneumoniae cell transformed with a plasmid of the invention may be useful in a vaccine composition. A nucleic acid construct comprising a nucleic acid sequence encoding a transposase enzyme and a promoter sequence, wherein the promoter sequence is active in M. hyopneumoniae; optionally wherein the promoter sequence comprises a promoter sequence from M. hyopneumoniae, or spiralin gene promoter of Spiroplasma citri or tetM promoter sequence from S. aureus; optionally wherein the promoter sequence from M. hyopneumoniae is a constitutively active promoter sequence, optionally a promoter sequence from the M. hyopneumoniae ldh, P97, secD, Tuf, rpoB, P146, ATP transporter ATP binding protein, Asparagine-tRNA synthetase or Translation elongation factor gene. The transposase enzyme may be a Mariner family transposase, optionally Himar1 transposase or Himar1 C9 mutant transposase.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• C12R 1/35 - Mycoplasma
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry- promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a &b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent. wherein: "n", refers to number of repeating units in the polymer, and n can vary from 2 to 1000, for example from 2 or 5 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800 or 900; G1 and G2 independently represent a cationic group comprising biguanide or guanidine, wherein L1, and L2 are directly joined to a Nitrogen atom of the guanide; L1 and L2 are linking groups between the G1 and G2 cationic groups in the polymer and independently represent an aliphatic group containing C1-C40 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, - C30, -C40, -C50 -C60 -C70, -C80, -C90, -C-100, -C110, -C120, -C130 or -C140, alkyl; or a C1-C140 (for example C1 , C2,C3, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, -C30, -C40, -C50 -C60, -C70, -C80, - C90, -C100, -C110, -C120, -C130o or -C140), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, or oxyalkylene radical; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups or saturated or unsaturated cyclic moiety; N and G3 are optional end groups; X can be either present or absent; L3, L4 and X are linking groups between the G4 and G5 cationic groups in the polymer and independently represent an aliphatic group containing C1-C140 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, -C30, - C40, -C50 -C60, -C70, -C80, -C90, -C100, -C110, -C120, -C130 or -C140, alkyl; or L3 and L4 and X can independently be C1-C140 (for example C1,C2, C3, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, -C30, -C40, -C50 -C60, -C70, -C80, -C90, -C100, -C110, -C120, -C130 or -C140), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, oxyalkylene radicals; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups as well as saturated or unsaturated cyclic moiety; "G4" and "G5" are cationic moieties and can be same or different, and at least one of them is a biguanidine moiety or carbamoylguanidine, and the other moiety may be biguanidine or carbamoylguanidine or amine; and cationic moieties G4 and G5 do not contain single guanidine groups. The entry-promoting agent may comprise homogeneous or heterogeneous mixture of one or more of agents arising from formulae 1 a and b, for example polyhexamethylene biguanide (PHMB), polyhexamethylene monoguanide (PHMG), polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB), polyethylene hexamethylene biguanide (PEHMB), polymethylene biguanides (PMB), poly(allylbiguanidnio-co-allylamine), poly(N- vinylbiguanide), polyallybiguanide.

IPC Classes  ?

• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

A device comprising an ambulatory aid, the device comprising a distal end, a load, a first portion positioned at, or close to the distal end and adapted to allow the device to move along a surface, a second portion spaced apart from the first portion and the distal end and adapted to allow a user to be attached to, or hold the device, and a power unit operably connected to the first portion, the device having a deployed position in which the device is moveable, and is supported by the user, movement of the device being powered by the power unit.

IPC Classes  ?

• A61H 3/04 - Wheeled walking aids for patients or disabled persons
• A61H 3/00 - Appliances for aiding patients or disabled persons to walk about

Abstract

Carriers are provided for transport of a substance across the blood-brain barrier. The carriers comprise an antibody specific for a target antigen, in particular, antibodies capable of binding to prion proteins. The antibodies are produced via methods which include adding a target antigen stabilising agent to a sample containing a target antigen, allowing the stabilising agent to stabilise the target antigen, incubating the stabilised target antigen with a conventional antibody immobilised on a solid support to form a complex, wherein the immobilised antibody is specific for the target antigen, immunising a host with the complex, and isolating antibodies specific for the target antigen from the host. Also provided are use of the carriers in treatment and diagnosis of disease, e.g. prion diseases.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

Methods are provided for producing an antibody specific for a target antigen, in particular, antibodies capable of binding to prion proteins. The methods include adding a target antigen stabilising agent to a sample containing a target antigen, allowing the stabilising agent to stabilise the target antigen, incubating the stabilised target antigen with a conventional antibody immobilised on a solid support to form a complex, wherein the immobilised antibody is specific for the target antigen, immunising a host with the complex, and isolating antibodies specific for the target antigen from the host. Also provided are antibodies produced by the methods together with their use in treatment and diagnosis of disease, e.g. prion diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies

Abstract

This invention involves compositions and methods for protecting animals from pestivirus infection and for treating animals infected with pestivirus. Pharmaceutical compositions containing E2 and NS3 from a pestivirus are used to protect animals or treat animals.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

Apparatus for identifying sub-optimal performance in a race animal comprises means for measuring frequency of stride of the race animal, means for measuring speed of the animal and means for processing data. The data processing means is configured to receive and process said stride frequency and speed in a predetermined manner so as to identify a predetermined physiological condition such as fatigue in the race animal. Also disclosed are apparatus for measuring performance of a rider.

IPC Classes  ?

• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

A composition for topical application to a subjects skin comprising a matrix metalloproteinase inhibitor, more particularly an inhibitor selected from the group consisting of : TIMP-I, TIMP-2, TIMP-3, TIMP-4, Ilomastat, MMP inhibitor 111, CL82198, GM1489, and FN-439 is used for the prevention or treatment of soft skeletal tissue extracellular matrix degeneration, more particularly wherein the soft skeletal tissue is a tendon or ligament, and more particularly where the tendon is -selected from the group consisting of : superficial digital flexor tendon (SDFT), suspensory ligament, deep flexor tendon, deep digital flexor tendon (DDFT), accessory ligament of the deep digital flexor tendon, cruciate ligament, Achilles tendon, flexor tendon, quadriceps tendon, rotator cuff, and lateral or medial epichondylitis, and more particularly wherein the musculoskeletal injury or disorder is selected from superficial digital flexor tendinopathy and suspensory ligament desmitis, Achilles tendon injuries, rotator cuff injury, lateral epicondylitis, medial epicondylitis and patellar tendinopathy.

IPC Classes  ?

• A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A spermatozoa diluent comprising isolated Hsc70 protein, in which the Hsc70 has sperm viability improving and/or prolonging activity. Also disclosed are compositions comprising the diluent, methods of prolonging/improving sperm viability and use of the diluent to prolong/improve sperm viability.

IPC Classes  ?

• A61K 35/52 - SpermProstateSeminal fluidLeydig cells of testes
• C12N 5/076 - Sperm cellsSpermatogonia

Abstract

A method of identifying an agent which modulates at least one activity or function of the Mycobacterium tuberculosis protein Rv3574 or an orthologue thereof from another actinomycete, the method comprising providing Rv3574 or the orthologue thereof, providing double stranded DNA (dsDNA) comprising the sequence X1X2X3AACX4X5GTX6X7X8X9 (SEQ ID No: 2) under conditions which allow the Rv3574 or the orthologue to bind to the dsDNA, providing a test agent, and determining whether the test agent modulates at least one activity or function of the M. tuberculosis Rv3574 or the orthologue thereof.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A method of inducing relaxation of the cervix of a female mammal, the method comprising administering at least one pharmaceutical agent selected from follicle stimulating hormone or a beta-subunit thereof, luteinizing hormone or a beta- subunit thereof, thyroid stimulating hormone or a beta-subunit thereof, and chorionic gonadotrophin or a beta-subunit thereof, topically to the cervix of the mammal. The method can be used to facilitate artificial insemination of the female mammal. Also provided are medicinal formulations containing one or more of these hormones formulated as topical preparations or vaginal suppositories. A device comprising a sponge or foam impregnated with the hormone or hormone mixture is also provided.

IPC Classes  ?

• A61K 38/24 - Follicle-stimulating hormone [FSH]Chorionic gonadotropins, e.g. HCGLuteinising hormone [LH]Thyroid-stimulating hormone [TSH]
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A method of identifying an N-terminally acetylated protein in a bacterium, the method comprising providing details of at least one putative translation start site (TSS) for at least one protein expressed in the bacterium, confirming the actual TSS of the at least one protein using mass spectrometry (MS), and determining whether the at least one protein is N-terminally acetylated using MS. A method of identifying an N-terminally acetylated protein in a bacterium, the method comprising providing a mutant strain of the bacterium comprising at least one protein N-acetyl transferase (pNAT) in mutant form, providing a wild-type strain of the bacterium comprising the at least one pNAT in wild-type form, and identifying a protein that is differentially N-terminal acetylated between the mutant and wild-type bacterial strains. A method of identifying a drug discovery target in a pathogenic bacterium, the method comprising determining at least one property of an N-terminally acetylated protein expressed in a pathogenic bacterium and which is relevant to the pathogenicity of the pathogenic bacterium. A method of identifying a bacterial pNAT. A method of screening for an inhibitor of a bacterial pNAT.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method for predicting or diagnosing hypertension in a mammal, the method comprising detecting the presence and/or level of anti-vimentin antibodies in a suitable sample obtained from the mammal. A method for predicting or diagnosing heart disease in a mammal, the method 0 comprising detecting the presence and/or level of anti-vimentin antibodies in a suitable sample obtained from the mammal.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

There is provided the use of a compound of general formula (I): in which: R1 represents hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C1-6 alkoxy, hydroxy C1-6 alkyl, C1-6alkylOC1-6 alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO2R29, CONR30 R31 or NR30R31; R2 represents a phenyl group, having phenyl ring B, substituted by a group selected from i) a 5 to 7 membered heterocyclic ring containing three heteroatoms selected from oxygen, nitrogen or sulphur, optionally substituted by a substituent selected from halogen, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C1-6 alkoxy, hydroxy C1-6 alkyl, C1-6 alkyl OC1-6 alkyl, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO2R29, CONR30 R31 NR30 R31, or NR30R31, formula (ii): or formula (iii): and optionally further substituted by one or two auxiliary substituents selected from a halogen atom, a hydroxy group, a C1-6 alkyl group, or by an auxiliary substituent selected from C3-6 cycloalkyl, C3-6 cycloalkenyl, hydroxy C1-6 alkyl, C1-6 alkylOC1-6alkyl, acyl, aryl, acyloxy, nitro, trifluoromethyl, cyano, CO22R29, CONR30 R31, or NR30 R31; D is CONH or NHCO; E is formula (A): or G-(CR24 R25)-NR27R28 where R5 represents a hydrogen atom or a C1-6 alkyl group, G is oxygen, S(O)p where p is 0, 1, or 2, NR32 where R32 is hydrogen, C1-6 alkyl or phenyl C1-6 alkyl, or G is CR24 = CR25 or CR24 R25 where R24 and R25 are independently hydrogen or C1-6 alkyl; F is hydrogen, a halogen atom, a hydroxy group, a C1-6 alkoxy group, a C1-6 alkyl group or a halogenated C1-6 alkyl group; R27 and R28 are independently hydrogen, C1-6 alkyl, aralkyl, or together with the nitrogen atom to which they are attached form an optionally substituted 5-to 7-membered heterocyclic ring containing one or two heteroatoms selected from oxygen, nitrogen or sulphur; R29, R30 and R31 are independently hydrogen or C1-6 alkyl; m is 1 to 4; and n is 1 or 2 or a physiologically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment or prophylaxis of laminitis.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis